Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998)

Leukemia

Volumn 18, Issue 10, 2004, Pages 1605-1610

  Wiernik, P H ^a   Paietta, E ^a   Goloubeva, O ^b,i   Lee, S J ^b   Makower, D ^c   Bennett, J M ^d   Wade, J L ^e   Ghosh, C ^f   Kaminer, L S ^g   Pizzolo, J ^a   Tallman, M S ^h  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c White Plains Hospital Center   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Decatur Memorial Hospital   (United States)

^f Iowa Blood and Cancer Care   (United States)

^g EVANSTON HOSPITAL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

Author keywords

Apoptosis; B cell CLL; Theophylline

Indexed keywords

AMINOPHYLLINE; ANNEXIN; CD45 ANTIGEN; CREATININE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; HEMOGLOBIN; METHYLXANTHINE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; THEOPHYLLINE;

ADULT; AGED; AGITATION; ANOREXIA; ANTIGEN BINDING; ANXIETY DISORDER; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BIOACCUMULATION; BLEEDING; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG RELEASE; DRUG RESPONSE; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; IN VITRO STUDY; INSOMNIA; LEUKEMIA CELL; LIGHT SCATTERING; LIVER DYSFUNCTION; LYMPHOCYTE; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TABLET; THROMBOCYTE DISORDER; VOMITING;

EID: 6344282963     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403494     Document Type: Article

References (43)

1. Banner KH, Page CP. Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Clin Exp Allergy 1996; 26 (Suppl. 2): 2-9.
2. Chung KF. Theophylline in chronic asthma - evidence for disease-modifying properties. Clin Exp Allergy 1996; 26 (Suppl. 2): 22-27.
3. Scordamaglia A, Ciprandis G, Ruffoni S, Caria M, Paolieri F, Venuti D et al. Theophylline and the immune response: in vivo and in vitro effects. Clin Immunol Immunopath 1988; 48: 238-246.
4. Jaffar Z, Sullivan P, Page CP, Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Resp J 1996; 9: 456-462.
5. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Resp Critical Care Med 1995; 151: 1907-1914.
6. Serafin WE. Drugs used in the treatment of asthma. In: Hardiman JG, Limbird LE, Molinoff PB, Ruddon RW (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw Hill, 1996, p 673.
7. McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol 1990; 145 1227-1230.
8. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta-1 and cyclic AMP promote apoptosis in resting B lymphocytes. J Immunol 1995; 154: 1634-1643.
9. Mentz F, Mossalayi MD, Ouaaz F, Baudet S, Issaly F, Ktorza S et al. Theophylline synergizes with chiorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 1996; 88: 2172-2182.
10. Mentz F, Merle-Beral H, Quaaz F, Binet JL. Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides. Br J Haemat 1995; 90: 957-959.
11. Binet JL, Mentz F, Leblond V, Merle-Beral H. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia. Leukemia 1995; 9: 2159-2161.
12. Binet JL, Mentz F, Leblond V, Merle-Beral H. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia. Leukemia 1995; 9: 2159-2161.
13. Makower D, Malik U, Novik Y, Wiernik PH. Therapeutic efficacy of theophylline in chronic lymphocytic leukemia. Med Oncol 1999; 6: 69-71.
14. International workshop on chronic lymphocytic leukemia. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria. Ann Intem Med 1989; 110: 236-238.
15. Simon R. Optimal two-stage designs for phase II clinical studies. Control Clin Trials 1989; 10: 1-10.
16. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
17. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer Verlag, 2000.
18. Bell PB, Rooney N, Bosanquet AG. CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. Cytometry 1999; 38: 102-105.
19. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia 1998; 12: 1013-1025.
20. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000; 243: 167-190.
21. Carbonari M, Cibati M, Cherchi M, Sbarigia D, Pesce AM, Dell'Anna L et al. Detection and characterization of apoptotic peripheral blood lymphocytes in HIV infection and cancer chemotherapy by a novel immunocytometric method. Blood 1994; 83: 1268-1277.
22. Clodi K, Kliche KO, Zhao S, Weidner D, Schenk T, Consoli U et al. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. Cytometry 2000; 40 19-25.
23. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 1998; 92: 2484-2494.
24. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular camp. Cell Signal 2002; 14: 277-284.
25. Basu S, Mitra Basu R. Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature. Haematologia 2000; 30: 225-227.
26. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC et al. Apoptosis sensitivity in 11 chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156: 2624-2630.
27. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-1062.
28. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukemia - the role of Bcl-2 family dysregulation. Leukemia Res 1999; 23: 1007-1014.
29. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different response to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88: 1365-1371.
30. Mentz F, Merle-Beral H, Dalloul AH. Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia 1999; 13: 78-84.
31. Consoli U, El-Tounsim I, Sandoval A, Snell V, Kleine H-D, Brown W et al. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998; 91: 1742-1748.
32. Yang E, Korsmeyer SJ. Molecular thanatoposis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386-401.
33. Reed JC. Chronic lymphocytic leukemia: a disease of dysregulated programmed cell death. Clin Immunol Newslett 1997; 17: 125-130.
34. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewsk S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
35. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haematol 1996; 95: 513-517.
36. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996; 69: 114-119.
37. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and lorr or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
38. H gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007.
39. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1269.
40. Tsuruda K, Yamada Y, Hirakata Y, Sugahara K, Maeda T, Atogami S et al. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms. Leukemia Res 1999; 23: 159-166.
41. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-1861.
42. Castejón R, Vargas JA, Romero Y, Briz M, Muñoz RM, Durántes A. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Cytometry 19991; 38: 224-230.
43. Oliveira GB, Pereira FG, Metze K, Lorand-Metze I. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Cytometry 2001; 46: 329-335.